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Systems biology studies have revealed transcriptional networks and proteomic signatures critical for embry-
onic stem cell (ESC) function. In this issue ofCell StemCell, Sampath et al. (2008) demonstrate that translation
is also differentially controlled in undifferentiated versus differentiated ESCs.Pluripotent embryonic stem cells (ESCs)
have the capacity to differentiate into all
adult cell lineages and thus offer much
hope for cell-based therapies of human
disease. However, to devise and optimize
protocols to engineer ESC-derived tis-
sues requires a comprehensive under-
standing of the networks controlling ESC
fate decisions. Because ESC differentia-
tion involves changes in numerous tran-
scriptional networks (Walker et al., 2007;
Ivanova et al., 2006), protein signaling
networks (Wang et al., 2006), and chro-
matin structure (Mikkelsen et al., 2007;
Pan et al., 2007), a systems biology
approach that integrates the transcrip-
tome, proteome, and promoter occu-
pancy data is needed to fully describe
the process of stem cell differentiation.
Underlying these networks are highly
refined control mechanisms, such as
miRNA that modulate the transcriptome
and are important for ES cell self-renewal
and differentiation (Lakshmipathy et al.,
2007; Ivey et al., 2008).
Currently, there are unresolved discrep-
ancies between the transcriptome and
proteome profiles of undifferentiated
ESCs and their differentiated progeny.410 Cell Stem Cell 2, May 2008 ª2008 ElseSpecifically, the level of gene expression
does not always correlate with protein
levels observed in the same populations.
A similar disconnect between mRNA and
protein expression has been observed in
lineage-specific differentiation systems,
such as hematopoiesis and myogenesis,
and might arise via regulatory mecha-
nisms that impact translational efficiency
and protein degradation rates. To bridge
this gap, some mRNA transcripts may be
primed for translation and are termed
‘‘potentiated’’ in yeast studies. These
mRNA can be identified by the isolation
of ribosome-enriched transcripts coupled
to microarray analysis, known as transla-
tional state array analysis (TSAA).
In this issue of Cell Stem Cell, Sampath
et al. (2008) delve into the translational
control of the mouse ESC transcriptome
during differentiation. The authors first
identified that during ESC differentiation
into embryoid bodies (EBs) there is an in-
crease in global mRNA and protein syn-
thesis. Using microarray analysis, they
verified that indeed there was an increase
in global transcript abundance in differ-
entiated ESCs. Interestingly, the vast
majority of ribosomes isolated from ESCsvier Inc.were not bound to mRNA, whereas the
elevated transcript and protein levels
observed in differentiated cells were cou-
pled with a significant increase in tran-
script loading of ribosomes. Thus, the
question that arises is whether there is
preferential loading of ribosomes with
transcripts that are important for ESC dif-
ferentiation. To address this possibility,
the authors conducted TSAA, a transcrip-
tome-wide method to identify polysome-
bound transcripts. Comparing the micro-
array datasets of transcript expression
with the ribosome loading results (the
TSSA dataset), the authors distinguished
four distinct groups: (1) transcripts that
were differentially expressed and differ-
entially loaded on ribosomes, (2) tran-
scripts that were differentially expressed
but exhibited no change in translational
efficiency, (3) transcripts that were not
differentially expressed but exhibited
changes in translational efficiency, and
(4) transcripts that did not change in abun-
dance or ribosome loading. It is important
to emphasize that ‘‘differential expres-
sion’’ of transcripts refers to the combined
number of signals that were either ele-
vated or reduced beyond a set threshold
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note, no discriminating trend was
observed with respect to the known
function of the genes in each group,
supporting the interpretation that
the regulatory patterns observed
were global, rather than targeted.
The authors go on to characterize
several genes selected from these
distinct groups. For example, tran-
scripts of Wnt1, a protein that has
been shown to be involved in stem
cell pluripotency and proliferation,
are expressed at the same level in
both ESCs and EBs; however,WNT1
protein expression in EBs is much
lower than ESCs. The authors attri-
bute this to decreased ribosome
loading, highlighting the importance
of translational control during ESC
differentiation.
To understand how translational
control is mediated during ESC
differentiation into EBs, the modula-
tion of 4EBP1 protein, an important
negative regulator of translational
initiation, was examined. During
ESC differentiation, 4EBP1 became
increasingly phosphorylated, as
would be expected given the global
elevation of protein levels observed
in these cells. Treating the cultures
with rapamycin, an inhibitor of the
mTOR pathway, blocked 4EBP1
phosphorylation. More importantly,
treatment with rapamycin severely
impaired the growth of EBs. To
explore the basis for the observed
defects, the authors identified the
mRNA-binding protein DAZL as
a target of the mTOR pathway.
Treatmentwith rapamycindecreased
DAZL translational efficiency, leading
to reduced protein levels. Because
DAZL is also an mRNA binding protein,
the authors propose a hierarchical model
for the regulation of translational effi-
ciency. One known target of DAZL, gua-
nine-rich sequence factor (GRSF), has
been shown to be critical for embryonic
development (Lickert et al., 2005), and
knockdown of Dazl resulted in a reduction
of GRSF protein levels. Together, these
results indicate that a cascade of
events from mTOR to 4EBP1, to DAZL,
to GRSF represents an important hierar-
chy in translational control of differ-
entiating ESCs. Given that EBs are com-
prised of heterogeneous populations, it
would be interesting to examine whether
rapamycin globally inhibits all differenti-
ated cells or if only specific lineages are
affected.
The molecular events that regulate the
balance between self-renewal and com-
mitment to differentiate are poorly under-
stood in all stem cells, including ESCs. In
their study, Sampath et al. (2008) highlight
an additional mechanism that appears to
participate in the control of ESC differen-
tiation. EBs offer an excellent model sys-
tem to study differentiation of ESCs into
all three germ layers; however, EBs are
composed of a heterogeneous population
of differentiating cells. It will be inter-
esting to compare the profiles of
ribosome-bound transcripts in EBs
to those of other ESC-guided differ-
entiation strategies such as removal
of self-renewal factors or treatment
with retinoic acid. Equally important
is to determine if a similar mecha-
nism is active at the genome-wide
level in somatic stem or progenitor
populations, such as neural precur-
sor cells (NPCs). Previous studies
have integrated transcriptome pro-
files and ChIP-chip data to identify
critical transcriptional networks
(Boyer et al., 2005; Walker et al.,
2007). As outlined in Figure 1, we
envision a process by which the in-
tegration of TSAA datasets with
transcriptome and promoter occu-
pancy data could further refine and
predict networks critical for ESC
commitment and differentiation.
Ultimately, this approach could
expand to integrate proteomic data-
sets such as those that track
protein-protein interactions or phos-
phorylation and other posttransla-
tional modifications in order to fully
define ESC pluripotency and differ-
entiation networks. Sampath et al.
(2008) have begun to bridge the
gap between transcriptome and
proteome profiles that arise during
ESC differentiation and are the
first to use a transcriptome-scale
analysis to demonstrate preferential
translation of transcripts during this
process.
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Early clinical trials designed to treat
mine neuron precursors yielded pr
recent papers describe longer-term
approaches that may lead to autolo
The first clinical trials that used dopamine
neuron replacement therapy for Parkin-
son’s disease (PD) were carried out in
Sweden almost 20 years ago by trans-
planting aborted fetal brain tissue into
the brains of PD patients (Lindvall et al.,
1990). Remarkably, the transferred tissue
harbored immature dopamine neurons
that integrated into the striatum, produced
dopamine, and in somecaseswereable to
replace drug treatments. However, initial
optimism faded when subsequent dou-
ble-blind trials revealed less substantial
effects and a few patients developed
dyskinesias, or abnormal movements
(Olanow et al., 2003; Freed et al., 2001).
Today, only a few clinical trials are still
ongoing as the field holds its breath and
waits for the answers to many technical
questions. Is there an alternative to using
fetal tissue? Will the transplanted cells
always be susceptible to rejection? Will
grafts succumb to the disease process
that killed the endogenous dopamine
neurons? Can troublesome dyskinesias
be avoided? Can dopamine neuron trans-
plants really provide a cure in a complex
disease like PD? Five new papers address
some of these issues and are the focus of
this article.
The use of fetal tissue as a cell source
for clinical transplantation is not very
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Parkinson’s disease by transplantat
omising results, but the approach r
outcomes in these patients, and
gous sources of transplantable dopa
practical, as developing dopamine neu-
rons are rare and only available from
exactly 8-week-old embryos. Cells from
younger donors will not be patterned cor-
rectly, and older cells will not survive. In
the early 1990s, researchers began to
ask whether stem cells might offer an al-
ternative. It quickly became evident that,
while human cells isolated from the fetal
tissue used in clinical transplantation
studies could be expanded in culture
and survive transplantation into rodent
models of PD, they failed to generate
significant numbers of dopamine neurons
when compared to primary tissues
(Svendsen et al., 1996). In a seminal pub-
lication by McKay and colleagues, this
problem was overcome by using mouse
embryonic stem cells (ESCs) as a starting
source. Unlike their fetal counterparts,
ESCs produce large numbers of func-
tional dopamine neurons that, when
transplanted, can restore function in
rodent models of PD (Kim et al., 2002).
This exciting work on ESCs has now
been extended in two important ways.
First, Studer and colleagues derived
murine embryos via nuclear transfer using
donor fibroblasts isolated from mice with
experimentally induced PD (Tabar et al.,
2008). The resulting blastocysts were
used to generate ESCs, whichwere differ-
ier Inc.Hughes, T.R., Zandstra, P.W., and Stanford, W.L.
(2007). Cell Stem Cell 1, 71–86.
Wang, J., Rao, S., Chu, J., Shen, X., Levasseur,
D.N., Theunissen, T.W., and Orkin, S.H. (2006).
Nature 444, 364–368.05, USA
ion of fetal tissue containing dopa-
etains several limitations. Multiple
two additional studies offer novel
mine neurons.
entiated into dopamine neurons and
transplanted back into the original fibro-
blast donor mice. Importantly, this study
observed improved graft survival and
functional recovery when autologous
ntESCs were transplanted, suggesting
that using exactly matched cells may
reduce immune rejection. In an indepen-
dent, but related, study, Jaenisch and
colleagues bypassed the need for nuclear
transfer with induced pluripotent stem
(iPS) cells derived by the enforced expres-
sion of four transcription factors in adult
fibroblasts (Yamanaka, 2007). Existing
murine iPS cell lines were differentiated
into neural lineages and then dopamine
neurons by using established techniques
(Wernig et al., 2008). The resulting cells
were subsequently transplanted into
a rat model of PD, where they elicited
functional improvement. In both of these
proof-of-principle studies, the authors
conclude that dopamine neurons pro-
duced from either clonedmouse embryos
or reprogrammed skin cells are able to
functionally integrate into the brain and
release dopamine—perhaps the best ob-
tainable evidence that neurons derived
using these methods can mature appro-
priately.
Of course, translating these exciting
mouse studies to human PD patients is
